# Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01892020` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01892020](<https://clinicaltrials.gov/study/NCT01892020>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01892020

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 161 participants.

## Technical summary

Registry record NCT01892020. Randomized; no masking; primary purpose treatment. Start 2013-06 (registry gives no type); primary completion 2014-05 (actual). Results posted on 2015-07-09.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 161 participants (enrolled count; ClinicalTrials.gov record NCT01892020, source copy `cardio:ctgov-nct01892020-2015-07-09`, retrieved 2026-10-26)
- Start date: 2013-06 (registry gives no type) (ClinicalTrials.gov record NCT01892020, source copy `cardio:ctgov-nct01892020-2015-07-09`, retrieved 2026-10-26)
- Primary completion: 2014-05 (actual) (ClinicalTrials.gov record NCT01892020, source copy `cardio:ctgov-nct01892020-2015-07-09`, retrieved 2026-10-26)
- Completion: 2014-05 (actual) (ClinicalTrials.gov record NCT01892020, source copy `cardio:ctgov-nct01892020-2015-07-09`, retrieved 2026-10-26)
- Results first posted: 2015-07-09 (ClinicalTrials.gov record NCT01892020, source copy `cardio:ctgov-nct01892020-2015-07-09`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01892020, source copy `cardio:ctgov-nct01892020-2015-07-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01892020-2015-07-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Investigating Efficacy and Safety of Biphasic Insulin Aspart 50 Twice Daily Versus Biphasic Human Insulin 50 Twice Daily Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): biphasic insulin aspart 50
- Intervention (Drug): biphasic human insulin 50
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 88b35ebe899f3198a30f6e5856038615a2336c8deb4b4fc91cac9b8f78de99c4
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
